Status:

RECRUITING

Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis

Lead Sponsor:

Institut du Cancer de Montpellier - Val d'Aurelle

Conditions:

Peritoneal Carcinomatosis

Pseudomyxoma Peritonei

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The investigator proposes to use the cardiac coherence technique to diminish anxiety before the surgery of a peritoneal carcinosis of colon or stomach or ovary and pseudomyxoma or peritoneal mesotheli...

Detailed Description

Facing a Peritoneal Carcinomatosis (PC) diagnosis requires significant psychological adjustments that may generate major distress because of heavy care and a sometimes poor prognosis. Psychological di...

Eligibility Criteria

Inclusion

  • Age over 18 years
  • Patients with peritoneal carcinosis awaiting cytoreductive surgery
  • Patients who scored strictly above 3 on the visual analogue anxiety scale and/or the psychological distress scale
  • Patients with sufficient command of the French language
  • Patient affiliated to a French social security system
  • Patient hospitalized at the Institute of cancer of Montpellier the day before his cytoreductive surgery (at T1 = D-1)
  • Signing of informed consent before any specific trial procedure

Exclusion

  • Patients who already have daily practice of cardiac coherence
  • Presence of proven psychiatric disorders (e.g., mental retardation, psychotic disorders, learning disabilities, attention deficit/hyperactivity, bipolar disorder, etc.) other than mood disorders that are reactive to the disease experience, or receiving psychotic treatment that may impair thinking, judgment or discernment
  • Physical or sensory inability to respond to questionnaires
  • Patients who have had a heart transplant or bypass surgery in the Year before surgery
  • Patient with a history of uncontrolled neurological pathology within the last 6 months before inclusion in the trial
  • Patients with a history of psychoactive substance dependence (excluding smoking) in the last 6 months before inclusion in the trial
  • Patients with brain metastases
  • Known natural bradycardia 50 beats per minute
  • Beta-blocker intake in progress
  • Ongoing cardiac arrhythmias
  • Known severe heart failure with ventricular ejection fraction strictly Below 40 %
  • Chronic uncontrolled pain and making it difficult to practice the technique
  • Patient with chronic obstructive pulmonary disease
  • Legal incapacity (patient under guardianship or curatorship)

Key Trial Info

Start Date :

September 21 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT04024917

Start Date

September 21 2021

End Date

December 1 2025

Last Update

January 10 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

ICM

Montpellier, Hérault, France, 34298